Abstract
Triple negative breast cancer (TNBC) is a highly heterogeneous disease, which influences the therapeutic response and makes difficult the discovery of effective targets. This heterogeneity is attributed to the presence of breast cancer stem cells (BCSCs), which determines resistance to chemotherapy and subsequently disease recurrence and metastasis. In this context, this work aimed to evaluate the morphological and phenotypic cellular heterogeneity of two TNBC cell lines cultured in monolayer and tumorsphere (TS) models by fluorescence and electron microscopy and flow cytometry. The BT-549 and Hs 578T analyses demonstrated large phenotypic and morphological heterogeneity between these cell lines, as well as between the cell subpopulations that compose them. BT-549 and Hs 578T are heterogeneous considering the cell surface marker CD44 and CD24 expression, characterizing BCSC mesenchymal-like cells (CD44+/CD24−), epithelial cells (CD44−/CD24+), hybrid cells with mesenchymal and epithelial features (CD44+/CD24+), and CD44−/CD24− cells. BCSC epithelial-like cells (ALDH+) were found in BT-549, BT-549 TS, and Hs 578T TS; however, only BT-549 TS showed a high ALDH activity. Ultrastructural characterization showed the heterogeneity within and among BT-549 and Hs 578T in monolayer and TS models being formed by more than one cellular type. Further, the mesenchymal characteristic of these cells is demonstrated by E-cadherin absence and filopodia. It is well known that tumor cell heterogeneity can influence survival, therapy responses, and the rate of tumor growth. Thus, molecular understanding of this heterogeneity is essential for the identification of potential therapeutic options and vulnerabilities of oncological patients.
Similar content being viewed by others
References
Abramson VG, Lehmann BD, Ballinger TJ (2015) Subtyping of triple-negative breast cancer: implications for therapy. Cancer 121:8–16. https://doi.org/10.1002/cncr.28914.Subtyping
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983–3988. https://doi.org/10.1073/pnas.0530291100
Anguiano M, Castilla C, Maška M, Ederra C, Peláez R, Morales X, Muñoz-Arrieta G, Mujika M, Kozubek M, Muñoz-Barrutia A, Rouzaut A, Arana S, Garcia-Aznar JM, Ortiz-de-Solorzano C (2017) Characterization of three-dimensional cancer cell migration in mixed collagen-Matrigel scaffolds using microfluidics and image analysis. PLoS ONE. https://doi.org/10.1371/journal.pone.0171417
Bischoff A, Huck B, Keller B, Strotbek M, Schmid S, Boerries M, Busch H, Müller D, Olayioye MA (2014) MiR149 functions as a tumor suppressor by controlling breast epithelial cell migration and invasion. Cancer Res 74:5256–5265. https://doi.org/10.1158/0008-5472.CAN-13-3319
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492
Caswell PT, Zech T (2018) Actin-based cell protrusion in a 3D matrix. Trends Cell Biol 28:823–834. https://doi.org/10.1016/j.tcb.2018.06.003
Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X, Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG, Perou CM, Lewis MT, Rosen JM, Chang JC (2009) Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA 106:13820–13825. https://doi.org/10.1073/pnas.0905718106
Daniel J, Coulter J, Woo J-H, Wilsbach K, Gabrielson E (2011) High levels of the Mps1 checkpoint protein are protective of aneuploidy in breast cancer cells. Proc Natl Acad Sci 108:5384–5389. https://doi.org/10.1073/pnas.1007645108
de Lima AB, Barbosa CDS, Gonçalves AMMN, Santos FVD, Viana GHR, Varotti FDP, Silva LM (2017) New 3-alkylpyridine marine alkaloid analogues as promising antitumor agents against the CD44+/high/CD24−/lowsubset of triple-negative breast cancer cell line. Chem Biol Drug Des 90:5–11. https://doi.org/10.1111/cbdd.12923
Ferrari-Amorotti G, Chiodoni C, Shen F, Cattelani S, Soliera AR, Manzotti G, Grisendi G, Dominici M, Rivasi F, Colombo MP, Fatatis A, Calabretta B (2014) Suppression of invasion and metastasis of triple-negative breast cancer lines by pharmacological or genetic inhibition of slug activity. Neoplasia 16:1047–1058. https://doi.org/10.1016/j.neo.2014.10.006
Fonseca NA, Filipa A, Moura V, Simões S, Nuno J (2017) The cancer stem cell phenotype as a determinant factor of the heterotypic nature of breast tumors. Crit Rev Oncol Hematol 113:111–121. https://doi.org/10.1016/j.critrevonc.2017.03.016
Ginestier C, Hur MH, Charafe-jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer C, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1:555–567
Grosse-Wilde A, D’Hérouël AF, McIntosh E, Ertaylan G, Skupin A, Kuestner RE, Del Sol A, Walters KA, Huang S (2015) Stemness of the hybrid epithelial/mesenchymal state in breast cancer and its association with poor survival. PLoS ONE 10:1–28. https://doi.org/10.1371/journal.pone.0126522
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. https://doi.org/10.1016/j.cell.2011.02.013
Haynes B, Sarma A, Nangia-Makker P, Shekhar MP (2017) Breast cancer complexity: implications of intratumoral heterogeneity in clinical management. Cancer Metastasis Rev 36:547–555. https://doi.org/10.1007/s10555-017-9684-y
Huber JM, Amann A, Koeck S, Lorenz E, Kelm JM, Obexer P, Zwierzina H, Gamerith G (2016) Evaluation of assays for drug efficacy in a three-dimensional model of the lung. J Cancer Res Clin Oncol 142:1955–1966. https://doi.org/10.1007/s00432-016-2198-0
Ishiguro T, Ohata H, Sato A, Yamawaki K, Enomoto T, Okamoto K (2017) Tumor-derived spheroids: Relevance to cancer stem cells and clinical applications. Cancer Sci 108:283–289. https://doi.org/10.1111/cas.13155
Jacquemet G, Hamidi H, Ivaska J (2015) Filopodia in cell adhesion, 3D migration and cancer cell invasion. Curr Opin Cell Biol 36:23–31. https://doi.org/10.1016/j.ceb.2015.06.007
Jia D, Tan Y, Liu H, Ooi S, Li L, Wright K, Bennett S, Addison CL, Wang L (2015) Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo. Oncotarget. https://doi.org/10.18632/oncotarget.5819
Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, Lorenz K, Lee EH, Barcellos-Hoff MH, Petersen OW, Gray JW, Bissell MJ (2007) The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 1:84–96
Kim RK, Suh Y, Yoo KC, Cui YH, Kim H, Kim MJ, Kim IG, Lee SJ (2015) Activation of KRAS promotes the mesenchymal features of Basal-type breast cancer. Exp Mol Med 47:e137–e139. https://doi.org/10.1038/emm.2014.99
Kleinman HK, Martin GR (2005) Matrigel: Basement membrane matrix with biological activity. Semin Cancer Biol 15:378–386. https://doi.org/10.1016/j.semcancer.2005.05.004
Lamouille S, Xu J, Derynck R (2014) Molecular mechanisms of epithelial-mesenchymal transition. Natl Rev Mol Cell Biol 15:178–196. https://doi.org/10.1038/nrm3758.Molecular
Laurent J, Frongia C, Cazales M, Mondesert O, Ducommun B, Lobjois V (2013) Multicellular tumor spheroid models to explore cell cycle checkpoints in 3D. BMC Cancer. https://doi.org/10.1186/1471-2407-13-73
Lee C-H, Yu C-C, Wang B-Y, Chang W-W (2015) Tumorsphere as an effective in vitro platform for screening anti-cancer stem cell drugs. Oncotarget. https://doi.org/10.18632/oncotarget.6261
Lee GY, Kenny PA, Lee EH, Bissell MJ (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4:359–365. https://doi.org/10.1038/nmeth1015
Lehmann BDB, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750–2767. https://doi.org/10.1172/JCI45014DS1
Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y, Martin-Trevino R, Shang L, McDermott SP, Landis MD, Hong S, Adams A, D’Angelo R, Ginestier C, Charafe-Jauffret E, Clouthier SG, Birnbaum D, Wong ST, Zhan M, Chang JC, Wicha MS (2014) Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep 2:78–91. https://doi.org/10.1016/j.stemcr.2013.11.009
Luo M, Brooke M, Wicha MS (2015) Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance. Curr Pharm Des 21:1301–1310
Moreira MP, da Conceição Braga L, Cassali GD, Silva LM (2018) STAT3 as a promising chemoresistance biomarker associated with the CD44+/high/CD24−/low/ALDH+ BCSCs-like subset of the triple-negative breast cancer (TNBC) cell line. Exp Cell Res 363:283–290. https://doi.org/10.1016/j.yexcr.2018.01.018
Neve RM, Chin K, Fridlyand J, Yeh J, Frederick L, Fevr T, Clark L, Bayani N, Coppe J, Tong F, Speed T, Spellman PT, Devries S, Lapuk A, Wang NJ, Stilwell JL, Pinkel D, Albertson DG, Waldman FM, Dickson RB, Johnson MD, Lippman M, Ethier S, Gazdar A, Gray JW, Division LS, Berkeley L (2006) A collection of breast cancer cell lines for the study of functionally. Cancer Cell 10:515–527. https://doi.org/10.1016/j.ccr.2006.10.008.A
Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K (2010) Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16:876–887. https://doi.org/10.1158/1078-0432.CCR-09-1532
Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale A-L, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Natureure 406:747–752
Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12:R68. https://doi.org/10.1186/bcr2635
Rhodes LV, Tate CR, Hoang VT, Burks HE, Gilliam D, Martin EC, Elliott S, Miller DB, Buechlein A, Rusch D, Tang H, Nephew KP, Burow ME, Collins-Burow BM (2015) Regulation of triple-negative breast cancer cell metastasis by the tumor-suppressor liver kinase B1. Oncogenesis 4:1–8. https://doi.org/10.1038/oncsis.2015.27
Riffle S, Hegde RS (2017) Modeling tumor cell adaptations to hypoxia in multicellular tumor spheroids. J Exp Clin Cancer Res 36:1–10. https://doi.org/10.1186/s13046-017-0570-9
Riffle S, Pandey RN, Albert M, Hegde RS (2017) Linking hypoxia, DNA damage and proliferation in multicellular tumor spheroids. BMC Cancer 17:1–12. https://doi.org/10.1186/s12885-017-3319-0
Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, Yao J, Nikolskaya T, Serebryiskaya T, Beroukhim R, Hu M, Halushka MK, Sukumar S, Parker LM, Anderson KS, Harris LN, Garber JE, Richardson AL, Schnitt SJ, Nikolsky Y, Gelman RS, Polyak K (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11:259–273. https://doi.org/10.1016/j.ccr.2007.01.013
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale A-L (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci 98:10869–10874. https://doi.org/10.1073/pnas.191367098
Sun R, Shen S, Zhang YJ, Xu CF, Cao ZT, Wen LP, Wang J (2016) Nanoparticle-facilitated autophagy inhibition promotes the efficacy of chemotherapeutics against breast cancer stem cells. Biomaterials 103:44–55. https://doi.org/10.1016/j.biomaterials.2016.06.038
Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM (2012) Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res 14:R79. https://doi.org/10.1186/bcr3192
Tellez-Gabriel M, Ory B, Lamoureux F, Heymann MF, Heymann D (2016) Tumour heterogeneity: the key advantages of single-cell analysis. Int J Mol Sci. https://doi.org/10.3390/ijms17122142
Weiswald LB, Bellet D, Dangles-Marie V (2015) Spherical cancer models in tumor biology. Neoplasia (United States) 17:1–15. https://doi.org/10.1016/j.neo.2014.12.004
Yilmaz M, Christofori G (2009) EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28:15–33. https://doi.org/10.1007/s10555-008-9169-0
Zhang Z, Yang M, Chen R, Su W, Li P, Chen S, Chen Z, Chen A, Li S, Hu C (2014) IBP regulates epithelial-to-mesenchymal transition and the motility of breast cancer cells via Rac1, RhoA and Cdc42 signaling pathways. Br Dent J 217:3374–3382. https://doi.org/10.1038/onc.2013.337
Ziperstein MJ, Guzman A, Kaufman LJ (2015) Breast cancer cell line aggregate morphology does not predict invasive capacity. PLoS ONE 10:1–17. https://doi.org/10.1371/journal.pone.0139523
Funding
This work was financially supported through grants from Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) [grant number CBB-APQ-00054–12], Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
This article does not contain any studies with human participants or animals performed by any of the authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Moreira, M.P., Brayner, F.A., Alves, L.C. et al. Phenotypic, structural, and ultrastructural analysis of triple-negative breast cancer cell lines and breast cancer stem cell subpopulation. Eur Biophys J 48, 673–684 (2019). https://doi.org/10.1007/s00249-019-01393-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00249-019-01393-0